Thursday, October 01, 2020 12:31:06 AM
Dear Stockholder:
You are cordially invited to attend AIkido Pharma Inc.’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on Tuesday, November 17, 2020, at 9:00 a.m. Pacific Time/12:00 p.m. Eastern Time. The formal meeting notice and proxy statement for the Annual Meeting are attached.
The Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted via live webcast. You will be able to attend the Annual Meeting online, vote and submit your questions during the Annual Meeting by visiting www.virtualshareholdermeeting.com/AIKI2020.
https://www.otcmarkets.com/filing/html?id=14404041&guid=y5C6Ue0BaFkq7Zh
https://aikidopharma.com/
https://aikidopharma.com/portfolio/
https://aikidopharma.com/scientific-advisory-board/
https://ir.aikidopharma.com/sec-filings/
One Rockefeller Plaza
11th Floor
New York, NY 10020
Share Structure
Market Cap Market Cap
21,297,842
09/29/2020
Authorized Shares
200,000,000
03/02/2020
Outstanding Shares
34,920,219
08/05/2020
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
Not Available
Float
Not Available
https://www.otcmarkets.com/stock/AIKI/news/story?e&id=1699606
Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2)
Initial data reports one of the most critical genes for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003
NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.
Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and Hoth Senior Scientific Advisor, led the first phase of the study. "Thanks to Dr. Zippin and his team, we have gained insight and gathered significant data with regards to the significance of HT-003 in blocking acne pathogenic gene expression," stated Robb Knie, CEO of Hoth Therapeutics. "We will continue to monitor the data at lower doses and move onto the testing of rodent skin and carcinogenesis."
Initial data from the first phase of the research reports that one of the most critical genes for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003. In addition, HT-003 at doses as high as 50 µM led to no observable toxicity. During the next phase of the research, Dr. Zippin will identify the minimal effective dose required to block TLR2 signaling in response to a broad range of bacteria derived agonists to further elucidate the pathway.
"The ability of HT-003 to potently inhibit TLR2 expression suggests that this drug will not only be effective for acne but may also help a broad range of patients suffering from disease driven by over active inflammatory responses to bacteria," stated Dr. Zippin.
Once HT-003 biomarkers have been identified using thein vitro human keratinocytes models, testing will move onto into live rodents.
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM